Technical analysis of MapLight Therapeutics, Inc. (MPLT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
Price Performance
| 1 month | -3.55% |
| 3 months | -60.44% |
| Year-to-date | -35.12% |
52-Week Range
| 52-week High | $40.43 |
| 52-week Low | $9.10 |
| Avg Volume (90d) | 703K |
Technical Indicators
| SMA 50 | $18.98 |
| SMA 200 | $21.94 |
| Beta | -2.79 |
| 30-day Volatility (annualised) | 66.5% |
| Price vs SMA 50 | -39.9% |
| Price vs SMA 200 | -48.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $16.92 | |
| 2025-11 | $13.63 | -19.4% |
| 2025-12 | $17.57 | +28.9% |
| 2026-01 | $17.69 | +0.7% |
| 2026-02 | $17.27 | -2.4% |
| 2026-03 | $20.33 | +17.7% |
| 2026-04 | $31.87 | +56.8% |
| 2026-05 | $29.31 | -8.0% |
| 2026-06 | $35.84 | +22.3% |
| 2026-07 | $13.02 | -63.7% |
| 2026-08 | $12.97 | -0.4% |
| 2026-09 | $11.40 | -12.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $11.40 |
| Market Cap | $484M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.66 |
| EV / EBITDA | -4.56 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 16.52 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 20.51 |